Evidence map›Paper›PMID 41098101›Full record

ArticleHaematologica2026

Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers.

Peter May, Michael Rassner, Marion Hoegner, Wajma Shahbaz, Ralph Wäsch, Ana M G Martinez, Burkhard Schmidt, Sebastian Theurich, Monika Engelhardt, Florian Bassermann and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Peter MayDepartment of Internal Medicine III, School of Medicine and Health, TUM University Hospital, Technical University of Munich. peter.may@tum.de.
Michael RassnerDepartment of Hematology, Oncology, and Stem-Cell Transplantation, University Hospital Freiburg, Albert Ludwig University of Freiburg, Germany; Comprehensive Cancer Center Freiburg.
Marion HoegnerDepartment of Internal Medicine III, School of Medicine and Health, TUM University Hospital, Technical University of Munich.
Wajma ShahbazDepartment of Medicine III, LMU University Hospital, Ludwig-Maximilians-University Munich, Germany; Comprehensive Cancer Center Munich (CCCM), Germany; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany; Bavarian Cancer Research Center (BZKF).
Ralph WäschDepartment of Hematology, Oncology, and Stem-Cell Transplantation, University Hospital Freiburg, Albert Ludwig University of Freiburg, Germany; Comprehensive Cancer Center Freiburg.
Ana M G MartinezDepartment of Internal Medicine III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Germany; Center for Personalized Medicine, TUM University Hospital, Technical University of Munich.
Burkhard SchmidtHematology and Oncology Munich-Pasing Medical Care Centre GmbH (MVZ), Munich.
Sebastian TheurichDepartment of Medicine III, LMU University Hospital, Ludwig-Maximilians-University Munich, Germany; Comprehensive Cancer Center Munich (CCCM), Germany; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany; Bavarian Cancer Research Center (BZKF).
Monika EngelhardtDepartment of Hematology, Oncology, and Stem-Cell Transplantation, University Hospital Freiburg, Albert Ludwig University of Freiburg, Germany; Comprehensive Cancer Center Freiburg.
Florian BassermannDepartment of Internal Medicine III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Germany; Comprehensive Cancer Center Munich (CCCM), Germany; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany; Bavarian Cancer Research Center (BZKF), Germany; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich.
Johannes JungDepartment of Internal Medicine III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Germany; Comprehensive Cancer Center Munich (CCCM), Germany; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany; Center for Personalized Medicine, TUM University Hospital, Technical University of Munich, Germany; Department of Hematology and Medical Oncology, University Medical Center Göttingen.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41098101
PMCPMC13040149

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.